The MYC gene family (consisting of LMYC, MYC, and NMYC) continues to occupy a central yet enigmatic role in cancer biology as frequent oncogenic drivers that are frustratingly difficult to antagonize pharmacologically. Integrated genomic analyses across diverse cancer histotypes clearly show a landscape of somatic tumor mutations that is vast, with many genes of both known and unknown oncogenic function being mutated at low frequency or in rare tumor subsets. Such findings make it all the more striking that there remain cancer genes like MYC that appear to be activated in a majority of human tumors (1) . MYC is a remarkably promiscuous transcription factor, modulating the output of hundreds-to-thousands of genes through a canonical network of protein partners that make up the extended MYC-MAX interactome (reviewed in [2] ). Transactivation of target genes follows recruitment of histone acetyltransferases that promote a chromatin configuration conducive to transcription. While MYC serves to coordinate cell cycle entry with the requisite metabolic and synthetic programs required to meet the energy and biomass needs of a proliferative tumor cell (3) , it has been difficult to identify any single transcriptional output that is both required and sufficient for MYC's cancer role.
Gene expression profiles reveal that MYC's signaling output in cancer is broad, but also dependent on both cellular context and level of expression. Initial efforts to understand this variability focused on Myc as a DNA-binding transcription factor and explored its varied output as a product of differential binding at core promoter elements in its dedicated transcription program, influenced by the stoichiometry and competing activities of its protein interaction network to promote or inhibit transcription (4) . This view put the onus of transcriptional selectivity squarely on MYC and largely side-stepped the issues of genome accessibility, chromatin configuration, and histone context. Thereafter came a model of MYC as a more passive transcriptional amplifier, in which its nonselective recruitment to actively transcribed genes leads to further elevation of transcript levels (5, 6) . In this case, the inability to define a consensus oncogenic MYC signature reflects the argument that its output is almost entirely dependent on the chromatin context and prior transcriptional state of the cell.
As with much in biology, the reality is likely to be more complex. MYC output seems to be constrained by the chromatin landscape it is operating within, acting on the diverse subset of "MYC-target genes" that are accessible and marked by requisite histone modifications (7). However, MYC also actively participates in modifying the chromatin landscape to further sculpt transcriptional output, at both target genes locally and at intragenic regions more globally (8) . The degree to which these activities are engaged by overexpression of MYC as found in cancer cells, in contrast to physiological expression, remains to be determined. Similarly, the full repertoire of chromatin-modifying partners through which MYC genes may exert their influence has yet to be characterized.
In the current issue of JNCI, Yang et al. (9) describe one such partner for MYCN in the childhood tumor neuroblastoma, identifying KDM4B, a JmjC domain-containing histone demethylase, as a novel MycN-interacting protein that contributes to tumor progression. Neuroblastoma remains a fascinating model for assessing MYCN activities, as the gene is deregulated through high copy number somatic amplification in approximately 25% of tumors and independently predicts for an aggressive disease course. Although MYCN amplification is utilized as a prognostic biomarker for treatment stratification worldwide, it has yet to serve as an actionable therapeutic target, and a deeper understanding of its myriad biological functions may provide tractable opportunities. The authors sought histone demethylases that might interact with MycN in oncogenesis given the finding that MYCN-null neural progenitors not only fail to proliferate but manifest an increase in repressive chromatin marks, H3K9 di-and tri-methylation. This suggests a potential role for Myc in euchromatin maintenance via lysine demethylation activities (8) . Expression of 10 of 17 JmjC histone demethylase family members were found to be correlated with MYCN expression (eight of the 10 directly correlated) in a set of 88 diverse neuroblastomas. KDM4B had the strongest correlation, and this was replicated in additional neuroblastoma cohorts, with MYCN amplified tumors demonstrating highest KDM4B expression.
Functional studies demonstrated that KDM4B knock-down leads to reduced transcription of genes that largely overlap MYC's transcriptional output (using a variety of available "MYC signatures") without altering MycN protein levels. Conversely, knock-down of MYCN did not alter KDM4B mRNA or protein levels either, suggesting their coregulatory activities were not mediated through direct transcriptional regulation of each other. Instead, Kdm4b and MycN were shown to physically interact using both Flag-tagged proteins overexpressed in 293T cells and endogenous proteins in MYCN amplified neuroblastoma cells. Notably, this binding with MycN did not displace Max (or disrupt the DNA-binding domain) but did require both the PHD and Tudor domains of Kdm4b and the central acidic domain of MycN. The authors demonstrate colocalization of MycN, Kdm4b, and RNA polymerase II at sites of MycN transcriptional activity using ChIP-PCR, along with a relative reduction in H3K9 di-and tri-methylation. Shown both at steady state in neuroblastoma cells and dynamically in response to induced MycN activation, the inference is that MycN recruits Kdm4B to at least a subset of MycN target genes, leading to demethylation of its putative substrate H3K9-me2/me3, thereby removing repressive chromatin marks and facilitating transcription. A role for Myc proteins recruiting lysine demethylases to promote transcriptionally favorable histone marks has been previously suggested. In murine embryonic stem cells, Myc has been shown to functionally interact with the murine homologues of Kdm4b and Kdm4c (10), while Drosophila dMyc has been shown to interact with the histone demethylase Lid, inhibiting its activity on its substrate, H3K4 tri-methylation, preserving its active histone mark (11) .
So does Kdm4b support MycN's oncogenic output sufficiently that it is a candidate therapeutic target? Preclinical murine models using neuroblastoma xenografts genetically manipulated to have constitutive or conditional knock-down of KDM4B show inhibition of tumor growth over the short term, suggesting this possibility. KDM4B appears to coregulate almost half of the genes regulated by MYCN and these are enriched for cell cycle functions, providing a plausible mechanism for antitumor activity. However, a full two-thirds of the genes downregulated by KDM4B knock-down (in the same cellular context) were not shared with MYCN, suggesting MYC-independent mechanisms may also be relevant. The larger question going forward is how entangled is the MYC transcriptional network with recruited histone-modifying enzymes, and what role do these play in supporting both physiologic and oncogenic functions of MYC? Much remains to be learned and while medicinal chemists continue the daunting pursuit of drugging Myc directly, the work by Yang et al. serves as a reminder that additional opportunities to antagonize Myc signaling exist and ongoing investigation is warranted.
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